Safety and efficacy of anti-PD1 therapy for metastatic melanoma and non-small cell lung cancer in patients with concurrent viral hepatitis

被引：0
|
作者：
Kothapalli, A. [1 ]
Khattak, M. [2 ]
机构：
[1] Fiona Stanley Hosp, Dermatol, Perth, WA, Australia
[2] Fiona Stanley Hosp, Med Oncol, Perth, WA, Australia
来源：
AUSTRALASIAN JOURNAL OF DERMATOLOGY | 2018年 / 59卷
关键词：
PEMBROLIZUMAB; IPILIMUMAB;
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：79 / 79
页数：1
相关论文
共 50 条
  • [1] Safety and efficacy of anti-PD-1 therapy for metastatic melanoma and non-small-cell lung cancer in patients with viral hepatitis: a case series
    Kothapalli, Anita
    Khattak, Muhammad A.
    MELANOMA RESEARCH, 2018, 28 (02) : 155 - 158
  • [2] Efficacy and Safety of Addition of Anti-PD1 to Chemotherapy in Treatment of Non-Small Cell Lung Cancer
    Ru, Chu-Hui
    Zhuang, Yan-Bing
    COMBINATORIAL CHEMISTRY & HIGH THROUGHPUT SCREENING, 2018, 21 (10) : 711 - 717
  • [3] Resistance mechanisms in non-small cell lung cancer patients upon anti-PD1 therapy
    Hiltbrunner, S.
    Cords, L.
    Kasser, S.
    Freiberger, S.
    Kreutzer, S.
    Toussaint, N.
    Grob, L.
    Bihr, S.
    Rechsteiner, M.
    Soltermann, A.
    Bodenmiller, B.
    Curioni-Fontecedro, A.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 195 - 195
  • [4] The role of tumor-infiltrating lymphocytes (TILs) as a predictive biomarker of response to anti-PD1 therapy in patients with metastatic non-small cell lung cancer or metastatic melanoma
    Uryvaev, Anton
    Passhak, Maria
    Hershkovits, Dov
    Sabo, Edmond
    Bar-Sela, Gil
    MEDICAL ONCOLOGY, 2018, 35 (03)
  • [5] The role of tumor-infiltrating lymphocytes (TILs) as a predictive biomarker of response to anti-PD1 therapy in patients with metastatic non-small cell lung cancer or metastatic melanoma
    Anton Uryvaev
    Maria Passhak
    Dov Hershkovits
    Edmond Sabo
    Gil Bar-Sela
    Medical Oncology, 2018, 35
  • [6] Anti-PD1 Immune Checkpoint Inhibitor-Induced Bullous Pemphigoid in Metastatic Melanoma and Non-Small Cell Lung Cancer
    Schwartzman, Gabrielle
    Simpson, Meagan McGinley
    Jones, Ryan
    Schiavone, Kaitlyn
    Coffman, Marcedes
    Meyerle, Jon
    CUTIS, 2020, 105 (06): : E9 - E12
  • [7] Immune-related adverse events: Comparison of melanoma and non-small cell lung cancer patients treated with anti-PD1 therapy
    Duma, N.
    Azzouqa, A-G.
    Yadav, S.
    Hoversten, K.
    Reed, C.
    Sitek, A. N.
    Lou, Y.
    Molina, J.
    Halfdanarson, T.
    Leventakos, K.
    Joseph, R. W.
    Manochakian, R.
    Dronca, R.
    ANNALS OF ONCOLOGY, 2018, 29 : 432 - 432
  • [8] Efficacy of Anti-PD1/PD-L1 Therapy (IO) in KRAS Mutant Non-small Cell Lung Cancer Patients: A Retrospective Analysis
    Gianoncelli, Letizia
    Spitaleri, Gianluca
    Passaro, Antonio
    Radice, Davide
    Fumagalli, Caterina
    Del Signore, Ester
    Stati, Valeria
    Catania, Chiara Matilde
    Guerini-Rocco, Elena
    Barberis, Massimo
    De Marinis, Filippo
    ANTICANCER RESEARCH, 2020, 40 (01) : 427 - 433
  • [9] Imaging of Anti-PD1 Therapy Response in Advanced Non-Small Lung Cancer
    Katz, Sharyn
    Hammer, Mark
    Bagley, Stephen
    Aggarwal, Charu
    Bauml, Joshua
    Langer, Corey
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S553 - S554
  • [10] Lung Microbiota Influence Responses to Anti-PD1 Therapy in a Preclinical Model of Non-small Cell Lung Cancer
    Chang, M.
    Mccormick, C.
    Kwok, B.
    Li, Y.
    Kyeremateng, Y.
    Aktas, A.
    Singh, R.
    Singh, S.
    Li, Q.
    Kugler, M. C.
    Pass, H.
    Sterman, D. H.
    Wu, B. G.
    Segal, L. N.
    Tsay, J. J.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2024, 209
12345